Verstockt B - Search Results

1

Genetics of inflammatory bowel disease: beyond NOD2.

Mirkov MU, Verstockt B, Cleynen I. Mirkov MU, et al. Among authors: verstockt b. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):224-234. doi: 10.1016/S2468-1253(16)30111-X. Epub 2017 Feb 9. Lancet Gastroenterol Hepatol. 2017. PMID: 28404137 Review.

2

Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysis.

Vuyyuru SK, Nguyen TM, Hogan M, Raine T, Noor NM, Narula N, Verstockt B, Feagan BG, Singh S, Ma C, Jairath V. Vuyyuru SK, et al. Among authors: verstockt b. Inflamm Bowel Dis. 2024 Apr 3;30(4):651-659. doi: 10.1093/ibd/izad052. Inflamm Bowel Dis. 2024. PMID: 37002875

3

Effect of anastomotic configuration on Crohn's disease recurrence after primary ileocolic resection: a comparative monocentric study of end-to-end versus side-to-side anastomosis.

Bislenghi G, Vancoillie PJ, Fieuws S, Verstockt B, Sabino J, Wolthuis A, D'Hoore A. Bislenghi G, et al. Among authors: verstockt b. Updates Surg. 2023 Sep;75(6):1607-1615. doi: 10.1007/s13304-023-01561-0. Epub 2023 Jun 12. Updates Surg. 2023. PMID: 37308742

4

The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn's Disease.

Yogev D, Verstockt B, Dignass A, Focht G, Atia O, Dotan I, Vermeire S, Turner D. Yogev D, et al. Among authors: verstockt b. Inflamm Bowel Dis. 2023 Jul 5;29(7):1170-1174. doi: 10.1093/ibd/izac235. Inflamm Bowel Dis. 2023. PMID: 36350981

5

A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.

Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, Ferrante M, Van Assche G, Vermeire S. Billiet T, et al. Among authors: verstockt b. J Crohns Colitis. 2015 Dec;9(12):1120-6. doi: 10.1093/ecco-jcc/jjv156. Epub 2015 Sep 7. J Crohns Colitis. 2015. PMID: 26351386

6

Genetic Influences on the Development of Fibrosis in Crohn's Disease.

Verstockt B, Cleynen I. Verstockt B, et al. Front Med (Lausanne). 2016 May 30;3:24. doi: 10.3389/fmed.2016.00024. eCollection 2016. Front Med (Lausanne). 2016. PMID: 27303667 Free PMC article. Review.

7

Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.

Verstockt B, Van Assche G, Vermeire S, Ferrante M. Verstockt B, et al. Expert Opin Biol Ther. 2017 Jan;17(1):31-47. doi: 10.1080/14712598.2017.1258399. Epub 2016 Nov 18. Expert Opin Biol Ther. 2017. PMID: 27817215 Review.

8

Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?

Noben M, Verstockt B, de Bruyn M, Hendriks N, Van Assche G, Vermeire S, Verfaillie C, Ferrante M. Noben M, et al. Among authors: verstockt b. Gut. 2017 Dec;66(12):2193-2195. doi: 10.1136/gutjnl-2016-313667. Epub 2017 Feb 3. Gut. 2017. PMID: 28159838 No abstract available.

9

A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.

Verstockt B, Deleenheer B, Van Assche G, Vermeire S, Ferrante M. Verstockt B, et al. Expert Opin Drug Saf. 2017 Jul;16(7):809-821. doi: 10.1080/14740338.2017.1338273. Epub 2017 Jun 9. Expert Opin Drug Saf. 2017. PMID: 28573876 Review.

10

New treatment options for inflammatory bowel diseases.

Verstockt B, Ferrante M, Vermeire S, Van Assche G. Verstockt B, et al. J Gastroenterol. 2018 May;53(5):585-590. doi: 10.1007/s00535-018-1449-z. Epub 2018 Mar 19. J Gastroenterol. 2018. PMID: 29556726 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

146 results

Search Page